SecBot SecBot

NVCR drug pipeline

NovoCure Ltd · 2 rated drugs
$11.30
−4.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±19.7%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
2
1 bearish · 1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseApproved (FDA)
Time to marketAlready FDA-approved and launching (February 2026). Currently commercially available in the U.S. for locally advanced pancreatic cancer.

Optune Pax Updated Jun 30

What to watch

Watch the Q2 2026 earnings (late July/early August) for Optune Pax prescription and patient-start numbers to gauge the launch trajectory. The key to re-rating will be whether the commercial ramp can outpace the 2026 guidance midpoint of ~$700M total revenue. Also monitor Zai Lab's progress with China NMPA submission for a potential 2027 catalyst.

Bull case
  • First new treatment for locally advanced pancreatic cancer in nearly 30 years, addressing a major unmet medical need with no direct competitor, positions Optune Pax for potential standard-of-care adoption
  • Early commercial launch data is strong: within 7 weeks of FDA approval, NovoCure certified 868 healthcare providers and generated 169 prescriptions with 90 patient starts, suggesting rapid physician adoption
  • Analyst consensus is bullish: 10 Buy/Strong Buy ratings vs 3 Hold and 0 Sell, with a mean price target of $26 (roughly 116% upside from the ~$15.48 current price) and a high target of $46
Bear case
  • Clinical benefit is modest, a 2-month median overall survival improvement and median device usage of 62.1% vs the recommended 75% (18h/day) suggests patient adherence challenges; skin irritation occurred in ≥75% of patients
  • Reimbursement is a multi-year slog: management has stated it will take 1-2 years to work through private payer coverage and likely longer for Medicare, capping near-term revenue potential
  • Company remains deeply unprofitable: Q1 2026 net loss of ~$71M (-$0.62 EPS), burning cash while investing in commercial infrastructure and pipeline trials (KEYNOTE D58)
▼ bearish
Impact
PhaseFiled/PMA (Not Approvable Letter received)
Time to marketUncertain; the FDA rejected the current PMA application. NovoCure plans to meet with the FDA to discuss options that may not require additional clinical studies, but no timeline for a resubmission or potential approval has been established.

Optune Mya Updated Nov 9

What to watch

The FDA's Not Approvable Letter for Optune Mya removes a key pipeline catalyst. Watch for NovoCure's planned meeting with the FDA to see if a path forward emerges without additional clinical studies. Separately, the Dec 31, 2026 PDUFA for Optune Pax (a different device) in the same brain metastases indication remains a major upcoming binary for NVCR.

Bull case
  • The FDA raised no safety concerns about Optune Mya, only questions about the degree of clinical benefit, which may leave a path to approval through additional analysis or a modified submission.
  • NovoCure plans to meet with the FDA to explore options that would not require additional clinical studies, potentially preserving a faster timeline.
  • The company has a growing commercial portfolio of approved TTFields devices (Optune Gio for glioblastoma, Optune Lua for mesothelioma, Optune Pax for pancreatic cancer) generating record revenue of $193M in Q3 2026, up 16% YoY.
Bear case
  • The FDA issued a Not Approvable Letter for Optune Mya, citing uncertainty around clinical benefit, meaning the device failed to convince regulators of its efficacy for brain metastases from NSCLC.
  • There is no guarantee that discussions with the FDA or any future submission will lead to approval, and additional clinical studies may be required, adding time and cost.
  • The rejection comes after another NovoCure late-stage trial failure in June 2026, where early use of its TTFields therapy did not significantly improve overall survival in newly diagnosed glioblastoma.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Feb 11, 2026Optune PaxApproval+19.7%+8.8%

1 newer event for subscribers. See plans

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
PembrolizumabLUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)Phase 2Terminated31Feb 23, 2026
AtezolizumabEF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaPhase 2Completed84Nov 18, 2025
BevacizumabOptune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 MeningiomaPhase 2Completed20Aug 11, 2025